TY - JOUR
T1 - Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib
AU - Latagliata, Roberto
AU - Breccia, Massimo
AU - Castagnetti, Fausto
AU - Stagno, Fabio
AU - Luciano, Luigiana
AU - Gozzini, Antonella
AU - Ulisciani, Stefano
AU - Cavazzini, Francesco
AU - Annunziata, Mario
AU - Sorà, Federica
AU - Rossi, Antonella Russo
AU - Pregno, Patrizia
AU - Montefusco, Enrico
AU - Abruzzese, Elisabetta
AU - Crisà, Elena
AU - Musto, Pellegrino
AU - Tiribelli, Mario
AU - Binotto, Gianni
AU - Occhini, Ubaldo
AU - Feo, Costanzo
AU - Vigneri, Paolo
AU - Santini, Valeria
AU - Fava, Carmen
AU - Rosti, Giannantonio
AU - Alimena, Giuliana
PY - 2011/9
Y1 - 2011/9
N2 - To highlight dasatinib role in the elderly, 125 unselected patients with CP-CML aged >60 years resistant/intolerant to imatinib were retrospectively evaluated. Grade 3-4 haematological and extra-haematological toxicities were reported in 39 (31.2%) and 34 (27.2%) patients; grade 3-4 haematological toxicity was higher in patients with 140. mg starting dose (50.0% vs 19.6%, p = 0.001). Grade 3-4 pleuro-pericardial effusions occurred in 10 patients (8.0%). Dose reductions were more common in patients with 140. mg (88.4% vs 26.7%, p<0.001). Of 122 evaluable patients, 72 (59.1%) had cytogenetic response [12 (9.8%) partial, 60 (49.3%) complete]. Overall, 38/60 patients in complete CyR also achieved a molecular response. Cumulative OS at 24 and 48 months were 93.1% (95% CI 88.4-97.8) and 84.2% (95% CI 74.6-93.7). Dasatinib, at the recommended dose of 100. mg/day, is effective and safe also in unselected elderly subjects.
AB - To highlight dasatinib role in the elderly, 125 unselected patients with CP-CML aged >60 years resistant/intolerant to imatinib were retrospectively evaluated. Grade 3-4 haematological and extra-haematological toxicities were reported in 39 (31.2%) and 34 (27.2%) patients; grade 3-4 haematological toxicity was higher in patients with 140. mg starting dose (50.0% vs 19.6%, p = 0.001). Grade 3-4 pleuro-pericardial effusions occurred in 10 patients (8.0%). Dose reductions were more common in patients with 140. mg (88.4% vs 26.7%, p<0.001). Of 122 evaluable patients, 72 (59.1%) had cytogenetic response [12 (9.8%) partial, 60 (49.3%) complete]. Overall, 38/60 patients in complete CyR also achieved a molecular response. Cumulative OS at 24 and 48 months were 93.1% (95% CI 88.4-97.8) and 84.2% (95% CI 74.6-93.7). Dasatinib, at the recommended dose of 100. mg/day, is effective and safe also in unselected elderly subjects.
KW - Chronic Myeloid Leukaemia
KW - Dasatinib
KW - Elderly
KW - Safety
UR - http://www.scopus.com/inward/record.url?scp=80051471275&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80051471275&partnerID=8YFLogxK
U2 - 10.1016/j.leukres.2011.05.015
DO - 10.1016/j.leukres.2011.05.015
M3 - Article
C2 - 21705080
AN - SCOPUS:80051471275
VL - 35
SP - 1164
EP - 1169
JO - Leukemia Research
JF - Leukemia Research
SN - 0145-2126
IS - 9
ER -